The National Medical Products Administration (NMPA) has issued market approval for the implantable left ventricular assist system developed by China-based Shenzhen Core Medical Technology Co., Ltd. This marks the fourth such device to reach the market in China, expanding options for patients with advanced heart failure.
Product Composition and Clinical Applications
The product, which includes implanted parts, external components, and surgical accessories, is designed to work in conjunction with specific artificial blood vessels. It provides mechanical support for the blood circulation of patients suffering from advanced refractory left heart failure. The system is intended for use as a transitional treatment before heart transplantation or to aid in the restoration of heart function.
Core Technology and Clinical Benefits
The core technology of this heart assist system is its disc motor technology, which offers several advantages over traditional models. The system is structurally simpler, lighter in weight, smaller in size, and lower in power consumption. These features translate to clinical benefits such as smaller surgical incisions, faster patient recovery, a broader range of applicability, and a reduced risk of thrombosis due to heat generated by the blood pump.-Fineline Info & Tech
